Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MTHFR
REST API REST API
Homo sapiens
MTHFR is differentially expressed in 267 experiments: 134 organism parts: liver, blood, ... (132 more);, 194 disease states: normal, breast carcinoma, ... (192 more);, 88 cell types 350 cell lines 34 compound treatments and 78 other conditions.
Orthologs Mthfr (Rattus norvegicus)   MTHFR (Danio rerio)   F1MF22_BOVIN (Bos taurus)   E1BXL1_CHICK (Gallus gallus)   F6RK00_CIOIN (Ciona intestinalis)   Mthfr (Mus musculus)   MET13 (Saccharomyces cerevisiae)   mthfr (Xenopus laevis)   MTHFR (Canis familiaris)   (Compare orthologs)
Gene Ontology Term methylenetetrahydrofolate reductase (NADPH) activity, cytosol, oxidoreductase activity, cellular amino acid metabolic process, methionine metabolic process, methionine biosynthetic process, folic acid metabolic process, vitamin metabolic process, blood circulation, oxidation-reduction process, water-soluble vitamin metabolic process
InterPro Term Mehydrof_redctse, Fadh2_euk
Gene-Disease Assocation STROKE, ISCHEMIC, NEURAL TUBE DEFECTS, FOLATE-SENSITIVE, HOMOCYSTINURIA DUE TO DEFICIENCY OF N(5,10)-METHYLENETETRAHYDROFOLATE, THROMBOSIS, SUSCEPTIBILITY TO, HOMOCYSTEINEMIA, SCHIZOPHRENIA; SCZD, OROFACIAL CLEFT 1; OFC1
UniProt Accession Q9NY63, Q5SNW7, Q5SNW6, Q5SNW5, Q8IU73, Q8IU67, P42898
Search EB-eye ENSG00000177000
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
K562
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
SW480
2
E-MEXP-1014, E-GEOD-2509
MDA-MB-231
1
2
E-GEOD-5823, E-MTAB-62, E-TABM-420
NA19144
1
E-GEOD-19480
344 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (43 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-TABM-145, E-AFMX-5
plasma cell
2
E-GEOD-6691, E-MEXP-2360
mast cell
1
E-GEOD-3982
mononuclear cell
1
E-GEOD-6053
leydig cell
1
E-MTAB-25
CD19+ B cells (neg. sel.)
1
E-TABM-145
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-MTAB-680, ... (49 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
glioblastoma
2
E-MTAB-62, E-GEOD-4290
control
2
E-GEOD-20602, E-GEOD-21912
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
prostate carcinoma
1
2
E-MEXP-2034, E-MTAB-62, E-GEOD-96
188 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
control - interferon-gamma
1
E-GEOD-7216
MIG control
1
1
E-GEOD-15811
chloroguine
1
E-GEOD-5418
TNF
1
E-GEOD-15205
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-TABM-321, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-1956, E-MEXP-2069, ... (34 experiments)

individual id
studied in E-GEOD-19519

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.463 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM